Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 11 (2022) > Article

DOI: 10.14704/nq.2022.20.11.NQ66227

Synthesis, Characterization, and Anti-Cancer Evaluation of Paclitaxel Analogs

Nansi Shrivastava, Rakhi Mishra, Avijit Mazumder

Abstract

The number of reported cases of cancer is steadily increasing in both industrialized and developing countries. In spite of the fact that significant progress has been achieved in tumor biology, molecular genetics, and in the prevention, detection, and treatment of cancer over the last few years, adequate therapy remains elusive due to late diagnosis, inadequate strategies for addressing aggressive metastasis, and the lack of clinical procedures overcoming multidrug-resistant (MDR) cancer. Currently, as a low toxicity, high efficiency, and broad-spectrum natural anti-cancer drug, paclitaxel has been widely used against ovarian cancer, breast cancer, uterine cancer, and other cancers. The challenging and tedious task with the drug is its low oral bioavailability and permeability which laid down the drug under class IV of the biopharmaceutical classification system of the drug. In this study to overcome this challenge, we developed the derivative of paclitaxel with glucose conjugation which further was evaluated for their snit cancer action. The obtained result indicates that the conjugation with glucose moiety enhances the anti-cancer efficacy which indicates that analogs have better penetration in the cell as well as action.

Keywords

Paclitaxel, conjugation, glucose, anti-cancer

Full Text

PDF

References

?>